When it comes to cancer research, some of the brightest of minds call this place home. Cancer has affected just about everyone in some form or fashion. This can be either directly or indirectly. This dangerous disease has been around for many years as it negatively-effects the organs of the human body. As of today, cancer has been put on the ropes via antibody-based therapies. These are some of the most innovative cancer fighting medications on earth, and they have saved thousands of lives. Seattle Genetics of Bothell, Washington, is one of the most prominent oncology companies in the world, and it produces these advanced therapies on a consistent basis. Dr. Clay Siegall is the CEO of the company, and he has many years of experience working in this business. He’s known as a scientist, a doctor, a mentor and a philanthropist. Siegall is also well-accomplished as he is the author of 70 publications as well as the holder of 15 patents.
In order to take Seattle Genetics to the next level, international marketing is the way to go. Seattle Genetics doesn’t own the marketing rights to its most successful medication ADCETRIS, but it owns the rights for its newer drugs that are in its pipeline. By marketing its own products internationally, the company wouldn’t have to split-up its hard-earned profits with other investors. Siegall has taken the time to understand the dynamics of the game, and he has opened an office in the nation of Switzerland. This action will allow the company to do its very own international marketing. Unlike in years of the past, Siegall will no longer sell any international rights for any of the new medications that are coming out in the future. He has made this mistake years ago with ADCETRIS, but he won’t make this mistake again. In February 2017, Siegall placed a $2 billion bid for the commercialization rights of a cancer fighting drug because that specific company wasn’t structurally-sound. This goes to show just how important owning your own product rights truly is.
The future of cancer research is looking much brighter than before. Future antibody-based therapies will be entering the market soon and Seattle Genetics will remain in control of its own products.